治疗性蛋白质中半衰期延长和免疫性:机制,权衡和决策框架
Yingping Chen1, Yinchu Song1, Yiwen Xie1
1Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Biochemical pharmacology
|February 27, 2026
概括
本综述比较了六个主要的蛋白质半衰期延长平台,提供了一个框架来选择开发更长效生物制剂的最佳方法,并解决蛋白质治疗方面的挑战.
科学领域:
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
- 蛋白质工程是指蛋白质工程.
背景情况:
- 治疗性蛋白质提供显著的临床益处,但受到短血半衰期和免疫性限制.
- 现有的半衰期延长平台 (PEGylation,XTEN/PAS,糖基工程,Fc融合,基于HSA的,脂化) 经常被独立评估.
- 这些局限性阻碍了基于蛋白质的药物疗法的全部潜力.
研究的目的:
- 基于其机制,系统地比较主要蛋白质半衰期延长平台.
- 评估每个平台对药理动力学,组织分布,免疫性,稳定性和可制造性的影响.
- 为为下一代生物制剂选择适当平台提供决策框架.
主要方法:
- 六个已建立的半衰期延长平台的系统审查和机制驱动的比较.
- 评估平台对关键药理动力学和药理动力学参数的影响.
- 临床候选人和新兴混合设计的分析.
主要成果:
- 每个平台在半衰期延长,免疫性和可制造性方面都有明显的优点和缺点.
- 确定了管理平台性能的关键分子原则.
- 一项比较分析强调了根据治疗目标进行量身定制的平台选择的需要.
结论:
- 一个跨平台的工具包和决策框架可以指导长效蛋白疗法的合理设计.
- 解决免疫性预测和监管协调方面的挑战对于推动生物发展至关重要.
- 优化平台选择将导致更安全,更有效的基于蛋白质的药物.
相关概念视频
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
50
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
50
Biopharmaceutical Factors Influencing Drug Product Design: Overview
383
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
383
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Drug Products: Biologics, Biosimilars and Interchangeables
312
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
312
Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
384
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
384


